JAKARTA: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Three-Arm Study of SAR302503 in Patients with Intermediate-2 or High-Risk Primary Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF, or Post-Essential Thrombocythemia (ET) MF with Splenomegaly.